Immunology and Biotherapies
34.4K views | +1 today
Follow
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular.

Gilbert C FAURE's insight:

We use Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...                                                            Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantion on Immune monitoring of Immune therapies, 

http://www.scoop.it/t/immune-monitoring-1     by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

Thanks to K Maggon for joining us. @Krishan Maggon

 

No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Handbook: Biosimilars in the treatment of solid tumours

Developed with expert faculty, this 10-chapter handbook is available to view and download, allowing you to cascade what you have learned to your colleagues to support growth in knowledge and confidence across your institution.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Harnessing cytokines and chemokines for cancer therapy | Nature Reviews Clinical Oncology

Harnessing cytokines and chemokines for cancer therapy | Nature Reviews Clinical Oncology | Immunology and Biotherapies | Scoop.it
During the past 40 years, cytokines and cytokine receptors have been extensively investigated as either cancer targets or cancer treatments. A strong preclinical rationale supports therapeutic strategies to enhance the growth inhibitory and immunostimulatory effects of interferons and interleukins, including IL-2, IL-7, IL-12 and IL-15, or to inhibit the inflammatory and tumour-promoting actions of cytokines such as TNF, IL-1β and IL-6. This rationale is underscored by the discovery of altered and dysregulated cytokine expression in all human cancers. These findings prompted clinical trials of several cytokines or cytokine antagonists, revealing relevant biological activity but limited therapeutic efficacy. However, most trials involved patients with advanced-stage disease, which might not be the optimal setting for cytokine-based therapy. The advent of more effective immunotherapies and an increased understanding of the tumour microenvironment have presented new approaches to harnessing cytokine networks in the treatment of cancer, which include using cytokine-based therapies to enhance the activity or alleviate the immune-related toxicities of other treatments as well as to target early stage cancers. Many challenges remain, especially concerning delivery methods, context dependencies, and the pleiotropic, redundant and often conflicting actions of many cytokines. Herein, we discuss the lessons learnt from the initial trials of single-agent cytokine-based therapies and subsequent efforts to better exploit such agents for the treatment of solid tumours. A variety of cytokines have diverse antitumour and/or pro-tumour activities and, accordingly, alterations in cytokine networks contribute to cancer development and progression. Therefore, cytokines and their receptors have long been investigated as therapeutic agents or targets in oncology, although with mostly disappointing results. Herein, Propper and Balkwill discuss the lessons learnt from initial clinical trials of monotherapy approaches as well as subsequent strategies to better leverage cytokines and cytokine antagonists in the treatment of solid tumours.

















No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives - ScienceDirect

Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives - ScienceDirect | Immunology and Biotherapies | Scoop.it
Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of biologics, and in particular anti-tumour necrosis factor (ant…
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

CAR T cells produced in vivo to treat cardiac injury

CAR T cells produced in vivo to treat cardiac injury | Immunology and Biotherapies | Scoop.it
Fibrosis affects millions of people with cardiac disease. We developed a therapeutic approach to generate transient antifibrotic chimeric antigen receptor (CAR) T cells in vivo by delivering modifi...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

A stem cell journey in ophthalmology: From the bench to the clinic - Caras - 2021 - STEM CELLS Translational Medicine - Wiley Online Library

A stem cell journey in ophthalmology: From the bench to the clinic - Caras - 2021 - STEM CELLS Translational Medicine - Wiley Online Library | Immunology and Biotherapies | Scoop.it
Abstract Debilitating diseases of the eye represent a large unmet medical need potentially addressable with stem cell-based approaches. Over the past decade, the California Institute for Regenerati...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Professor Ann Ager

Professor Ann Ager | Immunology and Biotherapies | Scoop.it
Professor Ann Ager received her Ph.D. from Cambridge University where she studied inflammatory response in vascular endothelial cells. More recently, Ager moved to Cardiff University’s Division of Infection and Immunity, where her research focuses on T-cell trafficking in diseases such as virus infection, cancer, and Alzheimer’s disease.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline

Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline | Immunology and Biotherapies | Scoop.it
PURPOSETo increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) ...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Unproven stem cell treatment industry in the USA: a concerning boom - BioNews

Unproven stem cell treatment industry in the USA: a concerning boom - BioNews | Immunology and Biotherapies | Scoop.it
Stem cell research is incredibly important for providing insight into diseases such as Parkinson's, with the hope this might provide potential targets for future treatment. But there's a caveat: much work is still necessary both to discover the mechanisms behind these diseases, and where we do understand the mechanism to translate this research into safe and effective therapies. Currently, the range of illnesses for which there are proven treatments based on stem cells is minuscule. The only established safe and effective stem cell treatment is haematopoietic stem cell transplantation which is used for treating conditions including leukaemia and multiple sclerosis. Any other stem cell therapies are currently unproven and experimental and require full independent review and testing to make sure they are safe and effective.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity

Pfizer Vaccine Induces Immune Structures Key to Lasting Immunity | Immunology and Biotherapies | Scoop.it
In the armpit lymph nodes of people who had received the mRNA vaccine against SARS-CoV-2, researchers found germinal centers needed to generate long-lived antibody-making cells.
Irène Cai Yi's curator insight, December 8, 2021 5:07 PM
Est-ce que ça signifie que Pfizer Vaccine sont mieux que les autres vaccins contre COVID-19?
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Oral Immunization With Plant-Based Vaccine Induces a Protective Response Against Infectious Bursal Disease | Plant Science

Frontiers | Oral Immunization With Plant-Based Vaccine Induces a Protective Response Against Infectious Bursal Disease | Plant Science | Immunology and Biotherapies | Scoop.it
Infectious bursal disease virus (IBDV) is the etiological agent of an immunosuppressive and highly contagious disease that affects young birds causing important economic losses in the poultry industry worldwide.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Therapeutic Potential of Anti-Interferon α Vaccination on SjS-Related Features in the MRL/lpr Autoimmune Mouse Model | Immunology

Frontiers | Therapeutic Potential of Anti-Interferon α Vaccination on SjS-Related Features in the MRL/lpr Autoimmune Mouse Model | Immunology | Immunology and Biotherapies | Scoop.it
Sjögren’s syndrome (SjS) is a frequent systemic autoimmune disease responsible for a major decrease in patients’ quality of life, potentially leading to life-threatening conditions while facing an unmet therapeutic need. Hence, we assessed the immunogenicity, efficacy, and tolerance of IFN-Kinoid (IFN-K), an anti-IFNα vaccination strategy, in a well-known mouse model of systemic autoimmunity with SjS-like features: MRL/MpJ-Faslpr/lpr (MRL/lpr) mice. Two cohorts (with ISA51 or SWE01 as adjuvants) of 26 female MRL/lpr were divided in parallel groups, “controls” (not treated, PBS and Keyhole Limpet Hemocyanin [KLH] groups) or “IFN-K” and followed up for 122 days. Eight-week-old mice received intra-muscular injections (days 0, 7, 28, 56 and 84) of PBS, KLH or IFN-K, emulsified in the appropriate adjuvant, and blood samples were serially collected. At sacrifice, surviving mice were euthanized and their organs were harvested for histopathological analysis (focus score in salivary/lacrimal glands) and IFN signature evaluation. SjS-like features were monitored. IFN-K induced a disease-modifying polyclonal anti-IFNα antibody response in all treated mice with high IFNα neutralization capacities, type 1 IFN signature’s reduction and disease features’ (ocular and oral sicca syndrome, neuropathy, focus score, glandular production of BAFF) improvement, as reflected by the decrease in Murine Sjögren’s Syndrome Disease Activity Index (MuSSDAI) modelled on EULAR Sjögren’s Syndrome Diseas
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

HLA-independent T cell receptors for targeting tumors with low antigen density | Nature Medicine

HLA-independent T cell receptors for targeting tumors with low antigen density | Nature Medicine | Immunology and Biotherapies | Scoop.it
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor–CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR. We demonstrate that these HLA-independent T cell receptors (HIT receptors) consistently afford high antigen sensitivity and mediate tumor recognition beyond what CD28-based CARs, the most sensitive design to date, can provide. We demonstrate that the functional persistence of HIT T cells can be augmented by constitutive coexpression of CD80 and 4-1BBL. Finally, we validate the increased antigen sensitivity afforded by HIT receptors in xenograft mouse models of B cell leukemia and acute myeloid leukemia, targeting CD19 and CD70, respectively. Overall, HIT receptors are well suited for targeting cell surface antigens of low abundance. HLA-independent T cell receptors, in which the heavy and light chains of a chimeric antigen receptor are incorporated into the endogenous T cell receptor locus, are more effective than CD28-based chimeric antigen receptors at targeting tumors with low antigen expression.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

COVID vaccines safely protect pregnant people: the data are in

COVID vaccines safely protect pregnant people: the data are in | Immunology and Biotherapies | Scoop.it
Despite evidence that pregnant people are at high risk of serious disease, many remain unvaccinated.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance | PNAS

Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance | PNAS | Immunology and Biotherapies | Scoop.it
We have argued that vaccine resistance is substantially less problematic for human and animal health than is drug resistance because vaccine resistance is far less likely to evolve, and when it has evolved, the pronounced health benefits associated with vaccination have largely been retained.
No comment yet.
Rescooped by Gilbert C FAURE from EntomoNews
Scoop.it!

Un vaccin Covid-19 sorti de l'usine à papillons de nuit :

Un vaccin Covid-19 sorti de l'usine à papillons de nuit : | Immunology and Biotherapies | Scoop.it
Mit Nuvaxovid sind seit Dezember 2021 fünf COVID-19-Impfstoffe in der EU zugelassen. Das Besondere am Novavax-Vakzin: das Impfprotein wird in Insektenzellen hergestellt. Das klingt außergewöhnlicher als es eigentlich ist.


Impfstoff aus der Mottenfabrik

von Kathleen Gransalke
27.12.2021


Traduction du début de l'article :

 

Avec Nuvaxovid, cinq vaccins COVID-19 sont autorisés dans l'UE depuis décembre 2021. La particularité du vaccin Novavax : la protéine vaccinale est produite dans des cellules d'insectes. Cela semble plus extraordinaire que cela ne l'est en réalité.

 

Traduit avec www.DeepL.com/Translator (version gratuite)

 

[Image] Des lignées cellulaires de papillons de nuit et d'autres insectes servent d'usines à protéines dans la biotechnologie.


Via Bernadette Cassel
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Vaccinomics and a New Paradigm for the Development of Preventive Vaccines Against Viral Infections

Vaccinomics and a New Paradigm for the Development of Preventive Vaccines Against Viral Infections | Immunology and Biotherapies | Scoop.it
In this article we define vaccinomics as the integration of immunogenetics and immunogenomics with systems biology and immune profiling. Vaccinomics is based on the use of cutting edge, high-dimensional (so called “omics”) assays and novel ...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Distinguishing COVID-19 infection and vaccination history by T cell reactivity | bioRxiv

Distinguishing COVID-19 infection and vaccination history by T cell reactivity | bioRxiv | Immunology and Biotherapies | Scoop.it
bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Engaging innate immunity in HIV-1 cure strategies | Nature Reviews Immunology

Engaging innate immunity in HIV-1 cure strategies | Nature Reviews Immunology | Immunology and Biotherapies | Scoop.it
Combination antiretroviral therapy (ART) can block multiple stages of the HIV-1 life cycle to prevent progression to AIDS in people living with HIV-1. However, owing to the persistence of a reservoir of latently infected CD4+ T cells, life-long ART is necessary to prevent viral rebound. One strategy currently under consideration for curing HIV-1 infection is known as ‘shock and kill’. This strategy uses latency-reversing agents to induce expression of HIV-1 genes, allowing for infected cells to be cleared by cytolytic immune cells. The role of innate immunity in HIV-1 pathogenesis is best understood in the context of acute infection. Here, we suggest that innate immunity can also be used to improve the efficacy of HIV-1 cure strategies, with a particular focus on dendritic cells (DCs) and natural killer cells. We discuss novel latency-reversing agents targeting DCs as well as DC-based strategies to enhance the clearance of infected cells by CD8+ T cells and strategies to improve the killing activity of natural killer cells. Current strategies for HIV-1 cure have not been successful in eliminating the latent reservoir. This Review highlights potential therapeutic strategies that engage the immunology of dendritic cells and natural killer cells in efforts to achieve HIV-1 cure.
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

MyJournals.org - Science - 'Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis' (Frontiers in Medicine)

MyJournals.org - Science - 'Stem Cells Therapy for COVID-19: A Systematic Review and Meta-Analysis' (Frontiers in Medicine)...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020 | Immunology

Frontiers | T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020 | Immunology | Immunology and Biotherapies | Scoop.it
Immune responses to protein and peptide drugs can alter or reduce their efficacy and may be associated with adverse effects. While anti-drug antibodies (ADA) are a standard clinical measure of protein therapeutic immunogenicity, T cell epitopes in the primary sequences of these drugs are the key drivers or modulators of ADA response, depending on the type of T cell response that is stimulated (e.g., T helper or Regulatory T cells, respectively). In a previous publication on T cell-dependent immunogenicity of biotherapeutics, we addressed mitigation efforts such as identifying and reducing the presence of T cell epitopes or T cell response to protein therapeutics prior to further development of the protein therapeutic for clinical use. Over the past 5 years, greater insight into the role of regulatory T cell epitopes and the conservation of T cell epitopes with self (beyond germline) has improved the preclinical assessment of immunogenic potential. In addition, impurities contained in therapeutic drug formulations such as host cell proteins have also attracted attention and become the focus of novel risk assessment methods. Target effects have come into focus, given the emergence of protein and peptide drugs that target immune receptors in immuno-oncology applications. Lastly, new modalities are entering the clinic, leading to the need to revise certain aspects of the preclinical immunogenicity assessment pathway. In addition to drugs that have multiple antibody-derive
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists | Immunology

Frontiers | Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFα Antagonists | Immunology | Immunology and Biotherapies | Scoop.it
Drugs formulated from monoclonal antibodies (mAbs) are clinically effective in various diseases. Repeated administration of mAbs, however, elicits an immune response in the form of anti-drug-antibodies (ADA), thereby reducing the drug's efficacy. Notwithstanding their importance, the molecular landscape of ADA and the mechanisms involved in their formation are not fully understood. Using a newly developed quantitative bio-immunoassay, we found that ADA concentrations specific to TNFα antagonists can exceed extreme concentrations of 1 mg/ml with a wide range of neutralization capacity. Our data further suggest a preferential use of the λ light chain in a subset of neutralizing ADA. Moreover, we show that administration of TNFα antagonists result in a vaccine-like response whereby ADA formation is governed by the extrafollicular T cell-independent immune response. Our bio-immunoassay coupled with insights on the nature of the immune response can be leveraged to improve mAb immunogenicity assessment and facilitate improvement in therapeutic intervention strategies.
Gilbert C FAURE's insight:

be'lated sorry

Irène Cai Yi's curator insight, December 8, 2021 5:12 PM
Share your insight
Scooped by Gilbert C FAURE
Scoop.it!

COVID-19 vaccines for children

COVID-19 vaccines for children | Immunology and Biotherapies | Scoop.it
Earlier this month, the US Centers for Disease Control and Prevention (CDC) recommended Pfizer’s COVID-19 messenger RNA (mRNA) vaccine for children between 5 and 11 years of age—that’s 28 million children. Yet surveys show that 42 to 66% of parents o
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Frontiers | Immunogenicity of TNF-Inhibitors | Immunology

Frontiers | Immunogenicity of TNF-Inhibitors | Immunology | Immunology and Biotherapies | Scoop.it
Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either primary or secondary failure to TNFi due to ineffectiveness of the drug or adverse reactions. Secondary failure and adverse events can be related to the development of anti-drug antibodies (ADA). The earliest studies that reported ADA toward TNFi mainly used drug-sensitive assays. Retrospectively, we recognize this has led to an underestimation of the amount of ADA produced due to drug interference. Drug-tolerant ADA assays also detect ADA in the presence of drug, which has contributed to the currently reported higher incidence of ADA development. Comprehension and awareness of the assay format used for ADA detection is thus essential to interpret ADA measurements correctly. In addition, a concurrent drug level measurement is informative as it may provide insight in the extent of underestimation of ADA levels and improves understanding the clinical consequences of ADA formation. The clinical effects are dependent on the ratio between the amount of drug that is neutralized by ADA and the amount of unbound drug. Pharmacokinetic modeling might be useful in this context. The ADA response generally gives rise to high affinity IgG antibodies, but this response will differ between patients. Some patients will not reach the phase o
No comment yet.